Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 2/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 5/20 | 0.36 |
| ▸ | BTK | Q06187 | 5/20 | 0.35 |
| ▸ | EGFR | P00533 | 3/20 | 0.35 |
| ▸ | C1S | P09871 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21679536 | 0.82 | SLC18A3 (0.41) | MAP3K12ATRBTKEGFRSLC18A3 | |
| SCHEMBL21679537 | 0.82 | SLC18A3 (0.41) | MAP3K12ATRBTKEGFRSLC18A3 | |
| SCHEMBL24374736 | 0.80 | LGMN (0.42) | ALK | |
| SCHEMBL17642597 | 0.78 | SLC18A3 (0.42) | BTKEGFRSLC18A3TLR8TLR7 | |
| SCHEMBL17665174 | 0.78 | SLC18A3 (0.42) | BTKEGFRSLC18A3TLR8TLR7 | |
| SCHEMBL19897368 | 0.77 | CHRNB2 (0.43) | MAP3K12ATRBTKEGFR | |
| SCHEMBL17651735 | 0.77 | CHRNB2 (0.43) | MAP3K12ATRBTKEGFR | |
| SCHEMBL22296390 | 0.77 | SLC18A3 (0.41) | MAP3K12ATRBTKEGFRSLC18A3 | |
| SCHEMBL23865969 | 0.77 | SLC18A3 (0.44) | MAP3K12ATRBTKEGFRSLC18A3 | |
| SCHEMBL17642588 | 0.77 | SLC18A3 (0.41) | MAP3K12ATRBTKEGFRSLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043030-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-02-09 | — | — | US | disclosed |
| US-11478474-B2 | 2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-10-25 | — | — | US | disclosed |
| US-20220125785-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125785-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP3A4, CYP4B1, CYP3A5 | MAP3K12 3768/4885ATR 2309/4885ADAMTS5 4064/4885 |
| US-11478474-B2 | 2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitor | BTK, SYK, LCK | MAP3K12 169/4885ATR 789/4885ADAMTS5 4017/4885 |
| US-20230043030-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP3A43, CYP3A5, CYP11B2 | MAP3K12 4414/4885ATR 3674/4885ADAMTS5 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.